S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
S&P 500   5,088.80
DOW   39,131.53
QQQ   436.78
Warren Buffett uses his annual letter to warn about Wall Street and recount Berkshire's successes
Free Stock Analysis Report: See The True Value of Any Stock (Ad)
MarketBeat Week in Review – 2/19 - 2/23
Taiwan giant chipmaker TSMC opens first plant in Japan as part of key global expansion
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
A collection of the insights Warren Buffett offered in his annual letter Saturday
West Africa bloc lifts coup sanctions on Niger in a new push for dialogue to resolve tensions
Disturbing Truth About Biden's New Program To Seize Your Cash (Ad)
West Africa's ECOWAS bloc says it's lifting sanctions imposed on Niger over last year’s coup in a new push for dialogue
Macron booed by French farmers who blame him for not doing enough to support agriculture
NASDAQ:HALO

Halozyme Therapeutics (HALO) Stock Price, News & Analysis

$40.56
+0.84 (+2.11%)
(As of 02/23/2024 ET)
Today's Range
$39.75
$40.95
50-Day Range
$33.68
$40.56
52-Week Range
$29.85
$51.04
Volume
1.17 million shs
Average Volume
1.12 million shs
Market Capitalization
$5.14 billion
P/E Ratio
19.22
Dividend Yield
N/A
Price Target
$51.60

Halozyme Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Moderate Buy
2.70 Rating Score
Upside/​Downside
27.2% Upside
$51.60 Price Target
Short Interest
Bearish
5.84% of Float Sold Short
Dividend Strength
N/A
Sustainability
-1.12
Upright™ Environmental Score
News Sentiment
0.54mentions of Halozyme Therapeutics in the last 14 days
Based on 28 Articles This Week
Insider Trading
Selling Shares
$396,300 Sold Last Quarter
Proj. Earnings Growth
17.48%
From $3.26 to $3.83 Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

4.98 out of 5 stars

Medical Sector

11th out of 943 stocks

Biological Products, Except Diagnostic Industry

4th out of 154 stocks


HALO stock logo

About Halozyme Therapeutics Stock (NASDAQ:HALO)

Halozyme Therapeutics, Inc., a biopharma technology platform company, researches, develops, and commercializes proprietary enzymes and devices in the United States, Switzerland, Ireland, Belgium, Japan, and internationally. The company's products are based on the patented recombinant human hyaluronidase enzyme (rHuPH20) that enables delivery of injectable biologics, such as monoclonal antibodies and other therapeutic molecules, as well as small molecules and fluids. It offers Hylenex recombinant, a formulation of rHuPH20 to facilitate subcutaneous (SC) fluid administration for achieving hydration to enhance the dispersion and absorption of other injected drugs in SC urography and to enhance resorption of radiopaque agents; XYOSTED, an injection for SC administration of testosterone replacement therapy; NOCDURNA, a sublingual tablet to treat nocturia due to nocturnal polyuria; TLANDO, an oral formulation for testosterone replacement therapy; and ATRS-1902, a proprietary drug device combination product. The company also provides Herceptin (trastuzumab), Herceptin Hylecta, and Phesgo to treat breast cancer; Mabthera SC for the treatment of multiple blood cancer; HYQVIA to treat primary immunodeficiency disorders; and DARZALEX for patients with amyloidosis, smoldering myeloma, and multiple myeloma. In addition, it offers Epinephrine Injection to treat allergy and immunology; Sumatriptan injection for migraines; exenatide and teriparatide injections; Makena, a progestin drug to reduce the risk of preterm birth; and OTREXUP, a SC methotrexate injection for adults with severe active rheumatoid arthritis and severe recalcitrant psoriasis, as well as children with active polyarticular juvenile idiopathic arthritis. Further, the company provides ATRS-1902 for adrenal crisis rescue; ARGX-113; and ARGX-117 to treat severe autoimmune diseases in multifocal motor neuropathy. Halozyme Therapeutics, Inc. was founded in 1998 and is headquartered in San Diego, California.

HALO Stock Price History

HALO Stock News Headlines

Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Better Than Oil Stocks
The best way to profit from energy is NOT a stock...Rather, it's this little-known alternative investment. 
Halozyme Therapeutics Inc.
Breaking Down Halozyme Therapeutics: 7 Analysts Share Their Views
Earnings Preview: Halozyme Therapeutics
Halozyme Therapeutics earnings preview: what Wall Street is expecting
HALO Jun 2024 22.500 put
HALO Jun 2024 30.000 put
HALO Jun 2024 40.000 put
Halozyme Therapeutics (NASDAQ:HALO) Upgraded at StockNews.com
See More Headlines
Receive HALO Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Halozyme Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
11/02/2021
Today
2/24/2024
Next Earnings (Estimated)
5/14/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biological products, except diagnostic
Sub-Industry
Biotechnology
Current Symbol
NASDAQ:HALO
CUSIP
40637H10
Employees
393
Year Founded
1998

Price Target and Rating

Average Stock Price Target
$51.60
High Stock Price Target
$72.00
Low Stock Price Target
$40.00
Potential Upside/Downside
+27.2%
Consensus Rating
Moderate Buy
Rating Score (0-4)
2.70
Research Coverage
10 Analysts

Profitability

Net Income
$202.13 million
Pretax Margin
42.01%

Debt

Sales & Book Value

Annual Sales
$829.25 million
Cash Flow
$3.24 per share
Book Value
$0.66 per share

Miscellaneous

Free Float
123,781,000
Market Cap
$5.14 billion
Optionable
Optionable
Beta
1.22

Social Links

7 Stocks to Buy And Hold Forever Cover

Click the link below and we'll send you MarketBeat's list of seven stocks and why their long-term outlooks are very promising.

Get This Free Report

Key Executives

  • Dr. Helen I. Torley M.B. Ch. B. (Age 61)
    M.R.C.P., President, CEO & Director
    Comp: $1.45M
  • Ms. Nicole LaBrosseMs. Nicole LaBrosse (Age 41)
    Senior VP & CFO
    Comp: $727.04k
  • Dr. Michael J. LaBarre Ph.D. (Age 60)
    Senior VP & Chief Technical Officer
    Comp: $723.24k
  • Mr. Mark Snyder Esq.
    Chief Legal Officer
  • Ms. Cortney Caudill M.B.A.
    Chief Operations Officer
  • Ms. Tram Bui
    Head of Investor Relations & Corporate Communications
  • Ms. Amy Marinne Fox
    Chief Human Resources Officer
  • Dr. Steve Knowles MBBS
    Chief Medical Officer
  • Dr. Christopher Bryant Ph.D. (Age 63)
    Chief Manufacturing Officer & Head of Technical Operations
  • Ms. Kristin Schwartzbauer
    Head of Quality














HALO Stock Analysis - Frequently Asked Questions

Should I buy or sell Halozyme Therapeutics stock right now?

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Halozyme Therapeutics in the last twelve months. There are currently 3 hold ratings and 7 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "moderate buy" HALO shares.
View HALO analyst ratings
or view top-rated stocks.

What is Halozyme Therapeutics' stock price target for 2024?

10 equities research analysts have issued 12-month price objectives for Halozyme Therapeutics' stock. Their HALO share price targets range from $40.00 to $72.00. On average, they anticipate the company's stock price to reach $51.60 in the next year. This suggests a possible upside of 27.2% from the stock's current price.
View analysts price targets for HALO
or view top-rated stocks among Wall Street analysts.

How have HALO shares performed in 2024?

Halozyme Therapeutics' stock was trading at $36.96 on January 1st, 2024. Since then, HALO shares have increased by 9.7% and is now trading at $40.56.
View the best growth stocks for 2024 here
.

Are investors shorting Halozyme Therapeutics?

Halozyme Therapeutics saw a increase in short interest in the month of January. As of January 31st, there was short interest totaling 7,640,000 shares, an increase of 6.6% from the January 15th total of 7,170,000 shares. Based on an average daily trading volume, of 1,330,000 shares, the short-interest ratio is currently 5.7 days. Currently, 5.8% of the company's stock are short sold.
View Halozyme Therapeutics' Short Interest
.

When is Halozyme Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Tuesday, May 14th 2024.
View our HALO earnings forecast
.

How were Halozyme Therapeutics' earnings last quarter?

Halozyme Therapeutics, Inc. (NASDAQ:HALO) released its earnings results on Tuesday, November, 2nd. The biopharmaceutical company reported $1.48 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.42 by $1.06. The biopharmaceutical company had revenue of $115.83 million for the quarter, compared to analyst estimates of $101.94 million. Halozyme Therapeutics had a net margin of 33.96% and a trailing twelve-month return on equity of 248.20%. During the same period last year, the company posted $0.25 EPS.

What guidance has Halozyme Therapeutics issued on next quarter's earnings?

Halozyme Therapeutics issued an update on its FY 2024 earnings guidance on Tuesday, February, 20th. The company provided earnings per share guidance of 3.550-3.900 for the period, compared to the consensus EPS estimate of 3.510. The company issued revenue guidance of $915.0 million-$985.0 million, compared to the consensus revenue estimate of $961.1 million.

What is Helen Torley's approval rating as Halozyme Therapeutics' CEO?

12 employees have rated Halozyme Therapeutics Chief Executive Officer Helen Torley on Glassdoor.com. Helen Torley has an approval rating of 75% among the company's employees.

What other stocks do shareholders of Halozyme Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Halozyme Therapeutics investors own include Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), BlackRock (BLK), Chipotle Mexican Grill (CMG), Micron Technology (MU), Gilead Sciences (GILD), Athabasca Oil (ATH), NIC (EGOV), Allergan (AGN) and AbbVie (ABBV).

Who are Halozyme Therapeutics' major shareholders?

Halozyme Therapeutics' stock is owned by a number of institutional and retail investors. Top institutional investors include Vanguard Group Inc. (10.04%), Artisan Partners Limited Partnership (5.06%), GW&K Investment Management LLC (1.69%), TD Asset Management Inc (1.50%), Northern Trust Corp (1.49%) and Charles Schwab Investment Management Inc. (1.31%). Insiders that own company stock include Connie Matsui, Helen Torley, James M Daly, Jean-Pierre Bizzari, Jeffrey William Henderson, Kenneth J Kelley, Matthew L Posard, Michael J Labarre and Nicole Labrosse.
View institutional ownership trends
.

How do I buy shares of Halozyme Therapeutics?

Shares of HALO stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

Does Halozyme Therapeutics have any subsidiaries?
The following companies are subsidiares of Halozyme Therapeutics: Halozyme Holdings Ltd., Halozyme Inc., Halozyme Switzerland GmbH, and Halozyme Switzerland Holdings GmbH.
Read More
This page (NASDAQ:HALO) was last updated on 2/24/2024 by MarketBeat.com Staff